Orencia Outperforming Rituxan In RA, Bristol Says; Branded DTC To Start Soon
Executive Summary
Physicians more frequently prescribe Bristol-Myers Squibb's Orencia than Genentech/Biogen Idec's Rituxan for rheumatoid arthritis, Bristol Worldwide Pharmaceuticals President Lamberto Andreotti said
You may also be interested in...
Bristol Sprycel Clears FDA As First Second-Line Leukemia Agent
Bristol-Myers Squibb will be required to submit follow-up data from ongoing clinical trials to convert the accelerated approval of Sprycel for chronic myeloid leukemia to full approval, FDA said after clearing dasatinib June 28
Rituxan RA Approval Raises The Stakes, But With A Lower Price
Genentech/Biogen Idec are pricing Rituxan (rituximab) for rheumatoid arthritis at a lower cost for most patients than the closest comparable biologic, Bristol-Myers Squibb's Orencia (abatacept)
Bristol Will Use One Distributor To Ensure Patient Access For Orencia Launch
Bristol-Myers Squibb is launching its rheumatoid arthritis treatment Orencia (abatacept) through a sole distributor to ensure patient access while the firm works to expand its manufacturing capacity